Nurix Therapeutics, Inc.

NRIX • Biotechnology

$26.14

▲ +0.82 (+3.24%)

Current price

EarningsLatest report: Feb 28, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$2.88B

Growth

-11.8%

Cash Flow

0/5

Trend

Negative

Evidence

Positive revenue growth · 8.7%Manageable debt level · 0.1Healthy liquidity · 7.02Weak profitability

Financial data as of: Feb 28, 2026, 12:00 AM UTCLast earnings update: Apr 8, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$26.14

Change3.24%

Shares Out110.07M

Market Cap$2.88B

Enterprise Value$2.34B

52W Range8.20 - 23.09

Beta1.87

P/E-9.74

P/S40.09

P/B5.98

P/FCF-10.58

EV/Sales32.55

Price$26.14

Change3.24%

Shares Out110.07M

Market Cap$2.88B

Enterprise Value$2.34B

52W Range8.20 - 23.09

Beta1.87

P/E-9.74

P/S40.09

P/B5.98

P/FCF-10.58

EV/Sales32.55

EV/EBITDA-8.09

EV/FCF-8.59

Earnings Yield-10.26%

FCF Yield-9.45%

Dividend Yield0.00%

Gross Margin77.55%

Oper. Margin-3.40%

Profit Margin-3.15%

Debt/Eq0.10

Current Ratio7.02

Quick Ratio7.02

Revenue 5Y-11.75%

Target$34.67

Target Upside32.63%

Target Median$34.00

Target Range28.00 - 45.00

Volume5.33M

Avg Volume1.78M

EPS Surprise-0.03

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

89/100

Price Attractiveness

Cheap or expensive today

50/100

Why this score▼

Positive revenue growth · 8.7%Manageable debt level · 0.1Healthy liquidity · 7.02Weak profitability

Analyst view

Analyst sentiment and price target

NRIX

Analyst sentiment

Based on 19 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Price Target

2026-06-26

Low

$23.00

Mean

$33.00

Median

$32.50

High

$45.00

Company Overview

IPO: 7/24/2020

Industry: Biotechnology

P/B i: 5.98

Debt / Equity i: 0.10

Operating Margin: -340.16%

Net Margin: -314.90%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.10

Current Ratio: 7.02

Quick Ratio: 7.02

Status: Good

Insider Transactions

Recent executive and insider activity

Ring Christine

Transaction: 06/25/2026

SELL

Change

-28,935

Price

$20.06

Filing

06/25/2026

Type

SELL

Ring Christine

Transaction: 06/25/2026

SELL

Change

-13,333

Price

$7.26

Filing

06/25/2026

Type

SELL

Hansen Gwenn

Transaction: 06/25/2026

SELL

Change

-5,394

Price

$20.00

Filing

06/25/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Ring Christine	SELL	-28,935	$20.06	06/25/2026	06/25/2026
Ring Christine	SELL	-13,333	$7.26	06/25/2026	06/25/2026
Hansen Gwenn	SELL	-5,394	$20.00	06/25/2026	06/25/2026
Ring Christine	SELL	-3,422	$1.86	06/02/2026	06/02/2026
Ring Christine	SELL	-8,148	$16.60	06/02/2026	06/02/2026
GREGORY JULIA P	BUY	+31,250	$15.86	05/15/2026	05/15/2026
Baynes Roy D.	BUY	+31,250	$15.86	05/15/2026	05/15/2026
DANSEY ROGER D	BUY	+31,250	$15.86	05/15/2026	05/15/2026
Kapur Anil	BUY	+31,250	$15.86	05/15/2026	05/15/2026
Lacey David L.	BUY	+31,250	$15.86	05/15/2026	05/15/2026
Reinsdorf Judith A	BUY	+31,250	$15.86	05/15/2026	05/15/2026
Saltzman Edward C	BUY	+31,250	$15.86	05/15/2026	05/15/2026
Silva Paul M	BUY	+31,250	$15.86	05/15/2026	05/15/2026
van Houte Hans	SELL	-582	$17.18	05/05/2026	05/05/2026
Ring Christine	SELL	-8,148	$16.96	05/04/2026	05/04/2026
Ring Christine	SELL	-5,394	$16.76	05/01/2026	05/01/2026
Hansen Gwenn	SELL	-2,000	Not reported	04/30/2026	04/30/2026
Hansen Gwenn	BUY	+2,000	Not reported	04/30/2026	04/30/2026
Ring Christine	SELL	-2,000	Not reported	04/30/2026	04/30/2026
Ring Christine	BUY	+2,000	Not reported	04/30/2026	04/30/2026

About the Company

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Source - link

Peers

BBOT EYPT FTRE KOD KURA PHAT SEPN TNGX URGN XNCR

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Tuesday, September 8, 2026, at 3:00 p.m.

GlobeNewsWire

Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case

Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg. NRIX's financial runway is extended to ~3.5 years, reducing near-term dilution risk and enabling multi-indication expansion without sacrificing U.S. economics. Bexobrutideg's Phase 1 data show high response rates in CLL/SLL, with a pivotal Phase 3 trial aiming to demonstrate superiority over pirtobrutinib.

Seeking Alpha

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and inflammatory diseases, today announced that Wes Burwell has joined Nurix as its Chief Human Resources Officer (CHRO).

GlobeNewsWire

Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade

Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday after Royal Bank Of Canada raised their price target on the stock from $33.00 to $36.00. Royal Bank Of Canada currently has an outperform rating on the stock. Nurix Therapeutics traded as high as $26.04 and

Defense World

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, as well as potential royalties, and retains a U.S. co-development and co-promotion option BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has earned a $10 million milestone payment following the initiation by its collaborator, Sanofi, of the Phase 1 first-in-human clinical trial of SAR448272/NX-3911, an oral STAT6 degrader.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-04-08	-0.76	-0.79	-0.03
2026-01-28	-0.84	-0.82	0.02
2025-10-09	-0.84	-1.03	-0.19
2025-07-09	-0.71	-0.52	0.19
2025-04-08	-0.72	-0.67	0.05
2025-01-28	-0.67	-0.75	-0.08
2024-10-11	-0.67	-0.67	0
2024-07-11	-0.66	-0.71	-0.05
2024-04-10	-0.8	-0.76	0.04
2024-02-15	-0.51	-0.77	-0.26
2023-10-12	-0.69	-0.68	0.01
2023-07-13	-0.63	-0.45	0.18